Plaxgen

Plaxgen is a pre-clinical stage biotechnology company focused on the development of targeted nanomedicines for cardiovascular diseases, specifically targeting unstable atherosclerotic plaques. The company's platform technology utilizes specialized nanoparticles that home in on high-risk vascular lesions to deliver therapeutic agents directly to the site of disease. This localized approach is designed to enhance the efficacy of anti-inflammatory and anti-thrombotic treatments while significantly reducing the risk of systemic side effects, such as bleeding. Founded on research from Massachusetts General Hospital, Plaxgen aims to provide a precision medicine solution for preventing myocardial infarction and stroke.